1. Scrip
  2. >>New Products

BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients

REMS-Required Training And Certification Under Way

 
• By Mandy Jackson

Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.

Man in red shirt preparing for stair run
BMS and bluebird won the race to bring a BCMA-targeting CAR-T to market, but the climb to commercial success begins now • Source: Shutterstock

Bristol Myers Squibb Company and bluebird bio are bringing to market the first chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) and the first CAR-T therapy for multiple myeloma. BMS chief commercialization officer Chris Boerner told Scrip that the initial focus of the Abecma (idecabtagene vicleucel, ide-cel) launch is working to certify the first treatment centers to administer the one-time treatment following US Food and Drug Administration approval on 26 March.

Abecma, which is under review for approval in the EU, was approved by the FDA to treat relapsed or refractory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sobi Gets Ready To Take On Krystexxa In Uncontrolled Gout

 
• By Jessica Merrill

The company believes its novel treatment NASP could drive use in a category where medication is underutilized.

Corstasis Exploring All Options For Launch Of Enbumyst

 
• By Jessica Merrill

The nasal spray formulation of bumetanide was approved by the US FDA for edema associated with congestive heart failure and hepatic and renal disease.

Pipeline Watch: Seven Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Eyes On Icotrokinra As J&J Submits Oral Psoriasis Therapy

 
• By Kevin Grogan

The EMA is reviewing the IL-23-targeting oral peptide which the company claims will transform the plaque psoriasis treatment paradigm.

More from Scrip

EADV: Leo Makes A Big Leap With Eczema Drug Temtokibart Set For Phase III

 
• By Kevin Grogan

CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.

Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside

 
• By Manas Mishra

Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.